NCT06557603View on ClinicalTrials.gov

Bioequivalence Study of Ivermectin 1% Cream and Soolantra (Ivermectin) 10 mg/g Cream

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

March 6, 2024

Primary Completion Date

July 11, 2024

Study Completion Date

July 22, 2024

Conditions
Rosacea
Interventions
DRUG

Ivermectin cream

\[1 gm ± 0.030 gm\] of product was applied in a thin layer over the entire face (avoiding the eyes, lips, and mucous membranes).

DRUG

Soolantra ® (Ivermectin) cream

\[1 gm ± 0.030 gm\] of product was applied in a thin layer over the entire face (avoiding the eyes, lips, and mucous membranes).

Trial Locations (1)

390012

Cliantha Research Limited, Vadodara

All Listed Sponsors
lead

Humanis Saglık Anonim Sirketi

INDUSTRY

NCT06557603 - Bioequivalence Study of Ivermectin 1% Cream and Soolantra (Ivermectin) 10 mg/g Cream | Biotech Hunter | Biotech Hunter